Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Team Grant: Health Challenges in Chronic Inflammation Initiative (LOI)

McGill University

$20,000.00

ImmunoSeq: novel immunogenetic discovery tool and its translation to personalized medicine in Finnish and Canadian partnership

FY 2012-13

Summary
Genetic mapping has uncovered common risk variants for inflammatory disease. At a patient level these individual variants may not be predictive for disease prevention or targeting of treatment. The current understanding of inherited factors underlying chronic inflammation is incomplete, however, in part due to indirect methods used in the past. Sequencing technologies have rapidly advanced recently, but has not yet been widely applied to understand inflammatory disease. By developing a new genetic test, ImmunoSeq., directed at parts of the human genome important in inflammation we can directly isolate key disease-predisposing variants in asthma, rheumatoid arthritis, systemic lupus erythomatosus, multiple sclerosis, inflammatory bowel disease and graft versus host disease. ImmunoSeq. will yield insight on common inflammatory mechanisms between diseases to allow rational choice of new and existing treatments and individualized prediction of disease risk.
Program
Team Grant: Health Challenges in Chronic Inflammation Initiative (LOI)
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
276972
Name
Pastinen Tomi
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Team Grant: Health Challenges in Chronic Inflammation Initiative (LOI)
Projecttitle
ImmunoSeq: novel immunogenetic discovery tool and its translation to personalized medicine in Finnish and Canadian partnership
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$20,000
Cihrequipment2
$0
Programname2
Team Grant: Health Challenges in Chronic Inflammation Initiative (LOI)
Keyworddelim
Autoimmune Disease; Genetic Risk; Immune System; Inflammatory Disease; Personalized Medicine
Abstract
Genetic mapping has uncovered common risk variants for inflammatory disease. At a patient level these individual variants may not be predictive for disease prevention or targeting of treatment. The current understanding of inherited factors underlying chronic inflammation is incomplete, however, in part due to indirect methods used in the past. Sequencing technologies have rapidly advanced recently, but has not yet been widely applied to understand inflammatory disease. By developing a new genetic test, ImmunoSeq., directed at parts of the human genome important in inflammation we can directly isolate key disease-predisposing variants in asthma, rheumatoid arthritis, systemic lupus erythomatosus, multiple sclerosis, inflammatory bowel disease and graft versus host disease. ImmunoSeq. will yield insight on common inflammatory mechanisms between diseases to allow rational choice of new and existing treatments and individualized prediction of disease risk.
Competitiondate
201211
Approvedterm2
1 yr 0 mth
Pinamesdelim
Pastinen, Tomi; Lathrop, Mark
Approvedterm
1 an 0 mois
Cihrcontribution2
Inst of Infection & Immunity~ $20,000~ $0~